| Patient | Billie Holiday |
|---|---|
| Date of birth | 1993-04-07 |
| Identifiers | MRN HR-ML010-SYN; SSN (made up) 000-10-4472 |
| Document date | 2026-07-20 |
| Author | Constance Mayfield, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Three-month review after a return to opioid use six days ago. [S]
Ms. Holiday returns three months after starting buprenorphine. Eight days ago, on tour in another state, the pharmacy could not refill her buprenorphine because the insurer's prior authorization had lapsed. After two days without it she had withdrawal and strong cravings, and six days ago she used heroin twice. She tested the supply first and the fentanyl strip was positive; she used with her friend present and naloxone at hand, and she did not overdose. The pharmacy filled the prescription the next day, and she restarted buprenorphine that morning, after waiting until she felt withdrawal again as she had been taught; she has taken it daily since and has used no opioids for five days. She also drank more on the tour, most nights. She called the clinic as soon as she was home and wanted to be seen. She is ashamed and worried that she has lost her place in treatment. She has had no thoughts of suicide. She feels tired and low and has not been sleeping well. [S]
| Element | Detail |
|---|---|
| Return to use | Heroin twice, six days ago, after two days without buprenorphine |
| Cause of the gap | Lapsed prior authorization while on tour |
| Safety | Tested the supply (fentanyl positive); used with her friend present and naloxone at hand; no overdose |
| Buprenorphine | Restarted five days ago at 16 mg daily, without precipitated withdrawal |
| Alcohol | Drinking most nights on tour |
| Mood | Tired, low, ashamed; PHQ-9 11; item 9 scored 0 |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired; weight down 1.2 kg; no fever |
| Gastrointestinal | Negative | No nausea, vomiting, or diarrhea now |
| Integumentary | Negative | No injection-site redness or abscess |
| Psychiatric | Positive | Low mood, poor sleep, and shame after the return to use; no thoughts of suicide or self-harm |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Buprenorphine 8 mg and naloxone 2 mg sublingual film: half a film (4 mg) on day 1, then one film (8 mg) under the tongue daily | One film under the tongue daily after a 4 mg first dose | Sublingual route | 2026-04-20 to 2026-04-27 | completed | S |
| Buprenorphine 8 mg and naloxone 2 mg sublingual film, two films (16 mg) under the tongue once daily | Two films under the tongue once daily | Sublingual route | 2026-04-27 | active | S |
| Naloxone 4 mg nasal spray, one spray in one nostril for a suspected opioid overdose; may repeat every 2 to 3 minutes in alternating nostrils; call 911 | One spray (4 mg) in one nostril for suspected overdose; repeat every 2 to 3 minutes if there is no response | Nasal route | 2026-04-20 | active | S |
| Acamprosate 333 mg delayed-release oral tablet, two tablets (666 mg) by mouth three times daily | Two tablets by mouth three times daily | Oral route | 2026-04-27 | active | S |
| Thiamine 100 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-04-20 to 2026-10-19 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-07-20 | Body height | 165 | cm | S |
| 2026-07-20 | Body weight | 67.4 | kg | S |
| 2026-07-20 | Body mass index (BMI) [Ratio] | 24.8 | kg/m2 | S |
| 2026-07-20 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-07-20 | Diastolic blood pressure | 82 | mm[Hg] | S |
| 2026-07-20 | Heart rate | 86 | /min | S |
| 2026-07-20 | Respiratory rate | 16 | /min | S |
| 2026-07-20 | Body temperature | 36.8 | Cel | S |
| 2026-07-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-07-20 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 44 | U/L | 10-40 U/L | High | S |
| 2026-07-20 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 33 | U/L | 7-56 U/L | Normal | S |
| 2026-07-20 | Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma | 61 | U/L | 5-40 U/L | High | S |
| 2026-07-20 | Phosphatidylethanol [Mass/volume] in Blood | 164 | ng/mL | Below 20 ng/mL: abstinence or light drinking; 20 to 199: significant drinking; 200 or more: heavy drinking | High | S |
| 2026-07-20 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 11 | {score} | S |
Vital signs recorded on 2026-07-20; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Tired but well; blood pressure 128/82, pulse 86 |
| Skin | No injection marks, redness, or abscess |
| Eyes | Pupils normal in size; no signs of withdrawal |
| Psychiatric | Tearful at first, then engaged in planning; no signs of intoxication |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Opioid use disorder (heroin), severe; in early remission in a controlled environment at intake, five weeks after release from custody; on buprenorphine; synthetic modern episode linked to her documented heroin use | active | confirmed | F11.20 | S — Synthetic modern coding of the documented heroin addiction; language is person-first, and the code does not change with a return to use. |
| Alcohol use disorder, moderate; synthetic modern episode linked to her documented heavier drinking after her mother's death | active | confirmed | F10.20 | S — Synthetic modern coding of the documented drinking; the liver disease reported in her last year is not coded, because it was documented long after the episode. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Medication safety | Buprenorphine dose, adherence, cravings, withdrawal, and side effects | Every visit | Completed today | Gap of three days from a lapsed prior authorization, then restarted at 16 mg; no precipitated withdrawal |
| Self-management | Visit frequency | Every 1 to 2 weeks in the first month after starting, then every 2 to 4 weeks until stable | Completed today | Video check-ins every two weeks kept since the five-week visit; seen in person within days of her call |
| Laboratory | Urine drug testing, including fentanyl, explained as part of care rather than as a test of trust | At the start, then about monthly early in treatment and as needed | Completed today | Buprenorphine, norbuprenorphine, and norfentanyl, consistent with what she reported |
| Medication safety | Prescription drug monitoring program check | Before each buprenorphine prescription | Completed today | No other prescriptions |
| Medication safety | Naloxone at home and in her bag, and a trained companion | At the start; check and replace at each visit | Completed today | Not used; replaced with new test strips |
| Self-management | Overdose prevention: never using alone and fentanyl test strips | Every visit | Completed today | She tested the supply and used with a companion and naloxone; reinforced without judgment |
| Medication safety | Prescription continuity on tour (pharmacy, prior authorization, travel letter) | Before each tour | Completed today | Prior authorization renewed for twelve months; national pharmacy chain; early fill and travel letter |
| Self-management | Counseling and peer recovery support | Offered to everyone; not a condition of medication | Completed today | Weekly in-person counseling from now; peer coach |
| Survey | Drinking and PEth | PEth at intake and at each check while drinking continues; AUDIT-C yearly | Completed today | PEth 164 ng/mL, up from 96, with heavier drinking on tour |
| Medication safety | Acamprosate adherence and kidney function | Kidney function before starting; adherence every visit | Completed today | Taking it; midday reminder working |
| Medication safety | Thiamine | While drinking heavily | Completed today | Taking thiamine daily |
| Laboratory | Liver tests (AST, ALT, GGT, albumin, bilirubin) | At intake, then every 1 to 3 months while drinking is heavy, and yearly | Completed today | AST 44, ALT 33, GGT 61 U/L |
| Laboratory | FIB-4 fibrosis score | At intake; repeat in 6 to 12 months with ongoing drinking, and every 1 to 2 years | Up to date | 1.18 at intake; repeat at six months |
| Survey | Depression screen (PHQ-9) | At intake and at each recovery visit while symptoms are present | Completed today | PHQ-9 11, item 9 scored 0; interview does not show a depressive episode |
| Survey | Mood Disorder Questionnaire | At the evaluation of a new depressive episode | Not indicated | No depressive episode on interview and no history suggesting mania |
| Survey | Suicide and overdose risk review, safety plan, and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm; overdose risk after the gap reviewed; the safety plan updated; the 988 Suicide & Crisis Lifeline in her phone |
Goal progress:
Guideline basis: The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update (2020); Treatment Options for Substance Use Disorder (medications for opioid and alcohol use disorders) (2026); VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021); Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases (2019); Depression and Suicide Risk in Adults: Screening (2023); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026)
Follow-up: Weekly counseling. Preventive visit in six weeks with the PHQ-9. Call the clinic the same day if a refill fails or cravings rise. Next scheduled visit 2026-08-31: periodic adult preventive visit. [S]